Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: COMBIVENT RESPIMAT

« Back to Dashboard

Combivent Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are twenty-one patents protecting this drug.

The generic ingredient in COMBIVENT RESPIMAT is albuterol sulfate; ipratropium bromide. There are thirty-four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

Summary for Tradename: COMBIVENT RESPIMAT

Patents:21
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$573,179,000

Pharmacology for Tradename: COMBIVENT RESPIMAT

Clinical Trials for: COMBIVENT RESPIMAT

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Ventilator Adapters for Combivent Respimat
Status: Recruiting Condition: Pulmonary Disease, Chronic Obstructive

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
Status: Completed Condition: Asthma

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747Oct 7, 2011RXYes7,802,568<disabled>Y<disabled>
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747Oct 7, 2011RXYes7,284,474<disabled>Y<disabled>
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747Oct 7, 2011RXYes6,503,362<disabled>Y<disabled>
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747Oct 7, 2011RXYes6,453,795<disabled>Y<disabled>
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747Oct 7, 2011RXYes7,396,341<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc